November sees Sanofi-Regeneron dethroned after 6-month rule over top TV ad spender list

How the mighty have fallen. Regeneron and Sanofi's IL-4/13 immunology drug, Dupixent, has reigned the monthly top ad-spender charts since May. In November, however, Dupixent tumbled down to No. 7, with more than $23 million slashed from the ad budget for its three ads.

Slipping neatly into the top two spots were October's Nos. 2 and 3, Rybelsus and Ozempic, respectively, both Novo Nordisk GLP-1 diabetes drugs.